Evidence map›Paper›PMID 36770166›Full record

ArticleMaterials (Basel, Switzerland)2023

Lipoproteins as Drug Carriers for Cyclosporine A: Optimization of the Entrapment.

Mona M A Abdel-Mottaleb, Lorenza Boi, Marina Barra, Julie Colin, Luisa Berni, Arnaud Béduneau, Brice Moulari, Yann Pellequer

Abstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mona M A Abdel-MottalebDepartment of Pharmaceutics and Industrial Pharmacy, Ain Shams University, Cairo 11566, Egypt.ORCID 0000-0002-4017-1248
Lorenza BoiDepartment of Drug Science and Technology, University of Turin, 10125 Turin, Italy.
Marina BarraDepartment of Drug Science and Technology, University of Turin, 10125 Turin, Italy.
Julie ColinPEPITE EA4267, Labex LipSTIC (ANR-11-LABX-0021), Université Franche-Comté, F-25000 Besançon, France.
Luisa BerniDepartment of Drug Science and Technology, University of Turin, 10125 Turin, Italy.
Arnaud BéduneauPEPITE EA4267, Labex LipSTIC (ANR-11-LABX-0021), Université Franche-Comté, F-25000 Besançon, France.
Brice MoulariPEPITE EA4267, Labex LipSTIC (ANR-11-LABX-0021), Université Franche-Comté, F-25000 Besançon, France.ORCID 0000-0002-3784-2354
Yann PellequerPEPITE EA4267, Labex LipSTIC (ANR-11-LABX-0021), Université Franche-Comté, F-25000 Besançon, France.ORCID 0000-0003-4318-974X

Funding

Labex LipSTIC
6 · The paper itself

Abstract

Lipoproteins are natural nanostructures responsible for the transport of cholesterol and other lipids in the blood. They are characterized by having a lipophilic core surrounded by an amphiphilic shell composed of phospholipids, cholesterol and one or more apolipoproteins. Being endogenous carriers makes them suitable for drug delivery purposes. Here, we investigate the effect of lipoproteins' intricate composition on the entrapment efficiency of a model drug "Cyclosporine A" into the different types of lipoproteins, namely, HDL, LDL and VLDL. It was observed that the protein content of the lipoproteins had the highest effect on the entrapment of the drug with a correlation coefficient of 0.80, 0.81 and 0.96 for HDL, LDL and VLDL respectively. This was even confirmed by the effect of plasma on the association rate of lipoproteins and the drug. The second effective factor is the cholesterol concentration, while triglycerides and phospholipids had a negligible effect.

Indexed as

apolipoproteinscholesterolcyclosporine Aentrapmentlipoproteins

Identifiers

PMID36770166
PMCPMC9918909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.